From WikiProjectMed
(Redirected from Pankomab)
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targettumor specific glycosylation of MUC1
Clinical data
Other namesPankoMab-GEX, anti-TA-MUC1
ATC code
  • None
CAS Number
  • none

Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.[1] Gatipotuzumab is being developed by Glycotope GMBH [2] and is undergoing a phase II clinical trial for ovarian cancer.[3]


  1. ^ "Gatipotuzumab". Drug Dictionary. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
  2. ^ "Gatipotuzumab – Our first-in-class GlycoBody against the novel tumor-specific TA-MUC1 epitope". Glycotope GmbH.
  3. ^ Clinical trial number NCT01899599 for "PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer " at

External links

  • "Gatipotuzumab". Drug Information Portal. U.S. National Library of Medicine.